Skip to main content
. Author manuscript; available in PMC: 2018 Feb 1.
Published in final edited form as: Endocr Relat Cancer. 2016 Dec 20;24(2):83–96. doi: 10.1530/ERC-16-0175

Figure 4. CA in the presence of BPA and its analogues may involve ER-alpha (ESR1).

Figure 4

LNCaP and C4-2 Cells were treated with inhibitors for ER (ICI), ESR1 (MPP), ESR2 (PHTPP), AR (Bicalutamide), and GPR30 (G15) for 72 h in the presence and absence of BPA and its analogues as indicated. Cells were fixed and scored for number of cells with centrosome numbers ≥3. Significance was calculated relative to no inhibitor group. *p<0.05 **p<0.005 ***p<0.001. Bars, SE of three independent experiments.